Infections with H. pylori affect over 43 percent of the world’s population with a wide range of gastrointestinal disorders
Data builds on promising signal published last week, underscoring the importance of sotrovimab for early treatment of COVID-19
Preclinical data demonstrate sotrovimab, authorised in multiple countries around the world, retains activity against all tested variants of concern, including key mutations of Omicron
The study enrolled 639 patients, nearly 80% of whom had previously received a covalent BTK inhibitor
The regulatory decision follows promising results from RIVER-81
The acquisition reflects Johnson & Johnson’s push to strengthen its position in antibody engineering and next-generation oncology modalities
Advanced molecular diagnostics solution enables rapid, high-accuracy biomarker detection for precision oncology
The designation marks the first Breakthrough Therapy recognition for calderasib and is backed by positive results from the Phase 1 KANDLELIT-001 clinical trial
The filing is backed by results from the pivotal SERENA-6 Phase III trial
The decision clears the drug as a monotherapy for adults with unresectable, locally advanced or metastatic non-small cell lung cancer
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
